LOBEF (Lobe Sciences) Dividend Payout Ratio: 0.00 (As of Feb. 2026)


What is Lobe Sciences Dividend Payout Ratio?

Lobe Sciences LOBEF +15.11% Dividend Payout Ratio is 0.00 as of Feb. 2026. The stock has 2 warning signs investors should review. Among 134 Biotechnology companies, Lobe Sciences ranks worse than 746267.91% on this metric.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Lobe Sciences's Dividend Payout Ratio for the months ended in Feb. 2026 was 0.00.

The historical rank and industry rank for Lobe Sciences's Dividend Payout Ratio or its related term are showing as below:


LOBEF's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.445
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-07-01), the Dividend Yield % of Lobe Sciences is 0.00%.

Lobe Sciences's Dividends per Share for the months ended in Feb. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Lobe Sciences (OTCPK:LOBEF) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Lobe Sciences Dividend Payout Ratio Related Terms


Lobe Sciences Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences Dividend Payout Ratio Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LOBEF vs VRTX, REGN, ALNY: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, Lobe Sciences's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lobe Sciences Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's Dividend Payout Ratio falls into.



Lobe Sciences Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Lobe Sciences's Dividend Payout Ratio for the fiscal year that ended in Aug. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Aug. 2025 )/ EPS without NRI (A: Aug. 2025 )
=0/ -0.021
=N/A

Lobe Sciences's Dividend Payout Ratio for the quarter that ended in Feb. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Feb. 2026 )/ EPS without NRI (Q: Feb. 2026 )
=0/ -0.007
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
Lobe Sciences (LOBEF) has a Dividend Payout Ratio of 0.00 as of Feb. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Lobe Sciences and its competitors. According to the industry distribution chart, Lobe Sciences ranks #999999 out of 134 companies in the Biotechnology industry.
Is Lobe Sciences' Dividend Payout Ratio too high?
Lobe Sciences' current Dividend Payout Ratio is 0.00. Based on the distribution chart, Lobe Sciences ranks #999999 out of 134 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Lobe Sciences' Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lobe Sciences ranks #999999 out of 134 companies for Dividend Payout Ratio. This places Lobe Sciences in the lower half of its industry. The industry median Dividend Payout Ratio is 0.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Lobe Sciences and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lobe Sciences's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current Dividend Payout Ratio is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.